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Abstract
Introduction
Dose reductions are often required to avoid toxicity in combination therapy for advanced
cancers, but information on appropriate dose reductions in renal dysfunction is lacking. This
study assessed dose reductions of renally cleared oncology agents given in combination therapy
in the setting of renal dysfunction.
Methods
A database of 1,072 patients was screened to identify patients with renal dysfunction
(glomerular filtration rate < 60 mL/min) receiving oncology combination therapy with at least
one agent requiring dose reduction for renal insufficiency. The dose of the renal agent was
compared to the single-agent renal dosing recommendations to calculate a dose percentage.
Tolerability was determined from electronic medical records review.
Results
Thirty-three regimens (n = 25 patients) were identified: 11 included at least one targeted agent
(n = 8 patients) and 22 had only cytotoxic chemotherapy (n = 18 patients). The renal agent was
given at the recommended single-agent renal dose in ~50% of combinations; ~50% of all
regimens were tolerated, and only six combinations had dose reductions for toxicity. The
median final dose percentage was 100% of the recommended renal dose (range: 25% - 333%);
no significant differences were seen between groups (cytotoxic - tolerated, cytotoxic - not
tolerated, targeted - tolerated, targeted - not tolerated; p = 0.38). No significant differences
were observed between tolerated vs. non-tolerated (p = 0.97) or targeted vs. cytotoxic (p = 0.80)
regimens.
Conclusions
Dose reductions of renally cleared agents are highly variable in oncology patients with renal
dysfunction. Additional studies are needed to determine appropriate dosing adjustments in this
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Introduction
Combination treatment approaches have dramatically changed outcomes for numerous
advanced malignancies with high cure rates as has been seen in testicular cancer, acute
lymphocytic leukemia, and Hodgkin lymphoma [1]. The complicated and heterogeneous
molecular and biologic landscapes of metastatic tumors necessitate novel combination
therapeutic approaches to improve responses and overcome resistance [2-4]. Thus, novel
combinations of cytotoxic chemotherapy and targeted agents, as well as combined targeted
therapies, are increasingly being pursued.
Many patients with advanced solid tumors will require dose adjustments for renal dysfunction.
Prior studies indicate that 60.3% of patients had an estimated creatinine clearance (CrCl) < 89
mL/min with 16.6% at a CrCl < 60 mL/min (Cockcroft-Gault equation) [5]. Renal dysfunction
can occur from co-morbidities prior to cancer diagnosis, can be caused by cancer itself, or can
be due to the drugs used to treat cancer [6]. Although an evaluation and study of renal
dysfunction dosing are required for many drugs as part of the Food and Drug Administration
(FDA) approval, recommendations are limited to single-agent dose-reduction recommendations
[7]. Patients with renal dysfunction are generally excluded from combination therapy trials [8].
Thus, the dose reductions required to safely administer renally cleared drugs for combination
therapy in the setting of renal dysfunction is unknown.
The aim of the current pilot study was to determine the dose reductions of renally cleared
agents given in combination therapy at the University of California San Diego (UCSD) for
patients with renal dysfunction, to determine how dosing compared to single-agent
recommended renal dose reductions, and to understand how dosing affected the tolerability of
the regimens. 
Materials And Methods
This is a retrospective, descriptive, pilot study of patients enrolled in the University of
California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity
(UCSD-PREDICT) [9], which encompasses an institutional review board (IRB)-approved
observational cohort study at UCSD designed to learn more about personalized cancer therapy,
including dosing, response to treatment, and side effects. This study was performed in
accordance with the UCSD IRB guidelines for data analysis and for any investigational
treatments for which patients gave consent.
The pilot study evaluated the subset of PREDICT patients whose prior oncology treatment
regimens were documented in the PREDICT electronic database. This database had previously
been generated from a manual review of the electronic medical records. The database and
electronic medical records were accessed to determine prior oncology treatment regimens and
renal function at the start of each therapy. Patients were included who had documented renal
dysfunction (creatinine clearance by Cockcroft-Gault equation of less than 60 mL/min) and
received combination therapy with two or more chemotherapeutic agents where at least one
drug required a dose adjustment for the patient’s degree of renal dysfunction. Those who did
not receive their full care at UCSD for the entirety of the regimen were excluded as toxicity and
dose adjustments were not routinely available from outside records.
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Medication administration records, laboratory values, and physician notes were reviewed to
determine the dosing throughout the regimen for each drug in the combination and tolerability
of the regimen. The starting dose, final dose, and the lowest dose used were documented for all
drugs in the regimen. The dose of the drug(s) requiring dose reduction for renal failure in the
combination was compared to the recommended single-agent renal dose reduction to
determine the dose percentage. Single-agent renal dosing recommendations were determined
from package inserts and the clinical pharmacology resource [10]. Tolerability was assessed
through a chart review of physician notes. Regimens that required multiple delays in
administration (which was verified by physician notes) were discontinued due to toxicity or
were explicitly stated by the physician to be poorly tolerated were listed as not tolerated. If a
regimen was not tolerated at the starting dose, but side effects and dose delays resolved
following dose reduction, the combination was considered to be tolerated. Differences in the
initial and final dose percentages based on tolerability and type of regimen (targeted agent
included vs. exclusively cytotoxic agents) were compared using an analysis of variance
(ANOVA) which was performed in SAS (v. 9.4) (SAS Institute Inc., Cary, NC). Differences
between the dosing recommendation category as compared to the renal recommended dose
(lower vs. higher than or equal to the recommended renal dose; higher than vs. lower than or
equal to the recommended renal dose) were compared to tolerability using Fisher’s exact test in
SAS (v. 9.4).
Results
After review of the PREDICT database (n = 1,072 patients), 33 regimens met the inclusion
criterion (n = 25 patients). Eleven regimens included at least one targeted agent (n = 8 patients),
and 22 regimens were exclusively cytotoxic chemotherapy (n = 18 patients) (Figure 1). One
patient was represented in both categories. The most commonly encountered renally cleared
drug with a recommendation for dose reduction was carboplatin (n = 24 combinations); no
other agent was encountered more than four times. Baseline characteristics at the start of
therapy for each patient are shown in Table 1.
FIGURE 1: Study Design Consort Diagram
Patients were included who had a GFR < 60 mL/min at the start of therapy by the Cockgroft-Gault
calculation and were receiving combination therapy with at least one drug that required a dose
reduction for renal failure. One patient received a regimen with at least one targeted agent and
exclusively cytotoxic chemotherapy, and thus was included in both groups.
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GFR: glomerular filtration rate; PREDICT: Personalized Cancer Therapy to Determine Response
and Toxicity; n: number; UC: University of California
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 At least one targeted therapy(n = 8)
Cytotoxic therapy (n =
18) a
Gender N (%)  
Male 1 (12.5) 7 (38.9)
Female 7 (87.5) 11 (61.1)
Race N (%)   
White 5 (62.5) 10 (55.6)
Black - -
Hispanic - 2 (11.1)
Asian - 3 (16.7)
Other 3 (37.5) 3 (16.7)
Median Age at Start of Therapy (Range; years) 66.8 (41.4 - 86.2) 70.6 (37 - 85)
Median Number of Drugs in Regimen (Range) 3 (2 - 7) 2 (2 - 3)
Type of cancer N (%)  
Lung 2 (25) 9 (50)
CNS 1 (12.5) -
Blood 3 (37.5) 1 (5.6)
Skin 1 (12.5) -
Breast 1 (12.5) 2 (11.1)
GU - 1 (5.6)
GYN - 1 (5.6)
Head/Neck - 3 (16.7)
Liver - 1 (16.7)
Median creatinine clearanceb at the start of therapy
(range, mL/min)
40 (29 - 59) 51 (19 - 58)
TABLE 1: Patient Characteristics at the Start of a Regimen
a Subject with one regimen containing a targeted agent and two cytotoxic regimens was included in both the targeted and cytotoxic
therapy grouping for demographics; b Creatinine clearance calculated by the Cockcroft-Gault formula.
CNS: central nervous system; GU: genitourinary; GYN: gynecology; N: number
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The chemotherapy regimens, baseline creatinine clearance at the start of each regimen, dose
percentages, and tolerability are summarized in Tables 2-3. In only two of the 11 regimens
(18%) that included a targeted agent was the renal agent given at the recommended single-
agent renal dose, while in 13 of the 22 cytotoxic regimens (59%), the renally cleared agent was
administered at the recommended dose. Seven of the 33 total regimens had dose adjustments;
six required dose reductions (three had been started at or below the recommended single agent
renal dose and three had been started above the single agent renal dose) and one had a dose
increase. Three of the 11 targeted regimens (27%) included dose reductions of the renally
cleared drug during the course of treatment (two of the three regimens were started at a
reduced dose) as compared to three of the 22 cytotoxic regimens (14%) (none of the three
regimens were started at a reduced dose). In four of the 11 targeted regimens (36%), a tolerable
final dose was found; in 13 of the 22 cytotoxic regimens (59%), a tolerable final dose was found.
IDa
Baseline
CrClb
(mL/min)
Combination Regimen Renally AdjustedMedication(s)
Starting
Dose
Percentc
Final Dose
Percentc
Tolerable
(Y/N)d
1 29 bevacizumab, carboplatin,gemcitabine carboplatin 90% 60%
 e Y
2 35 bevacizumab, carboplatin,pemetrexed
carboplatin 100% 100%
N
pemetrexed CIf CIf
2 55 bevacizumab, cisplatin,pemetrexed cisplatin 133.30% 133.30% N
3 57 bevacizumab, carboplatin,erlotinib carboplatin 83.30% 66.70% N
4 33 CyBorDg cyclophosphamide 111.10% 111.10% Y
           
 4
                     
            29 VDR-PACE
h
lenalidomide 333.30% 333.30%
Y
cisplatin 100% 100%
cyclophosphamide 83.30% 83.30%
etoposide 100% 100%
4 40 lenalidomide carfilzomibdexamethasone vorinostat lenalidomide 250% 125% N
5 51 CyBorDg cyclophosphamide 111.10% 111.10% N
6 46 cetuximab carboplatin carboplatin 100% 100% Y
7 39 lenalidomide rituximab lenalidomide 25% 25% N
8 59 olaparib carboplatin paclitaxel carboplatin 50% 50% N
Median 40
- -
100% 100%
-
(Range) (29 – 59) (25% - 333%) (25% -333%)
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TABLE 2: Dosing, Tolerability, and Time-to-treatment Failure for Combination
Regimens with At Least One Targeted Therapy
a Patients receiving more than one regimen meeting the inclusion criteria are listed as separate rows in the table; b CrCl: creatinine
clearance based on the Cockcroft-Gault equation; c Dose percent: (dose administered divided by standard dose recommended for the
current renal function) x 100; d Regimens that were not tolerated had multiple delays in administration, were discontinued due to
toxicity, or were explicitly stated by the physician to be poorly tolerated were listed as not tolerated; e Lowest dose in regimen was
45% but was increased to a final dose of 60%; f Pemetrexed is contraindicated (CI) at a creatinine clearance of 45 mL/min or
less; g CyBorD: cyclophosphamide, bortezomib, and dexamethasone; h VDR-PACE: bortezomib, lenalidomide, dexamethasone,
cisplatin, doxorubicin, cyclophosphamide, and etoposide
IDa Baseline CrCl
b
(mL/min)
Combination
Regimen
Renally Adjusted
Medication(s)
Starting Dose
Per Centc
Final Dose
Per Centc
Tolerable
(Y/N)d
1 19 carboplatinvinorelbine carboplatin 50% 50% N
1 29
carboplatin
gemcitabinee
carboplatin 60% 60% Y 
9 57
carboplatin
gemcitabine
paclitaxel
carboplatin 100% 100% N
9 57 carboplatingemcitabine carboplatin 100% 100% N
10 50 fludarabinecytarabine
fludarabine 200% 200%
N
cytarabine 166.70% 166.70%
10 55 CLAG-Mf cytarabine 166.70% 166.70% Y
11 52 carboplatingemcitabine carboplatin 100% 100% N
12g 47 carboplatin paclitaxel carboplatin 83.30% 83.30% N
12g 54 carboplatin paclitaxel carboplatin 83.30% 83.30% Y
13 46 carboplatingemcitabine carboplatin 120% 100% N
14 52 carboplatinpemetrexed carboplatin 80% 100% Y
15 44 carboplatin paclitaxel carboplatin 120% 80% N
16 53 carboplatinpemetrexed carboplatin 100% 100% Y
carboplatin
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17 48 gemcitabine carboplatin 120% 100% N
18 51 carboplatin paclitaxel carboplatin 100% 100% Y
19 58 carboplatin etoposide carboplatin 100% 100% Y
20 44 carboplatingemcitabine carboplatin 100% 100% Y
21 51
cyclophosphamide 
cyclophosphamide 111.10% 111.10% Y
doxorubicin
22 43 carboplatinpemetrexed carboplatin 100% 100% Y
23 48 carboplatin etoposide carboplatinetoposide
100% 80%
Y
100% 66.70%
24 55 carboplatinpemetrexed carboplatin 100% 100% Y
25 58 carboplatin docetaxel carboplatin 100% 100% Y
Median 51
- -
100% 100%
-
(Range) (19 – 58)             (50% -200%)
      (50% -
200%)
TABLE 3: Dosing, Tolerability, and Time-to-Treatment Failure for Combination
Regimens with Only Cytotoxic Chemotherapy
a Patients receiving more than one regimen meeting the inclusion criteria are listed as separate rows in the table; b CrCl: creatinine
clearance based on the Cockcroft-Gault equation; c Dose percent: (dose administered divided by standard dose recommended for the
current renal function) x 100; d Regimens that were not tolerated had multiple delays in administration, were discontinued due to
toxicity, or were explicitly stated by the physician to be poorly tolerated were listed as not tolerated; e Gemcitabine may require a dose
adjustment at a creatinine clearance less than 30 mL/min; however, no formal recommendation has been provided; f CLAG-M:
cladrabine, cytarabine, G-CSF, and mitoxantrone; g carboplatin and paclitaxel were administered as two separate treatments during the
patient's disease treatment with different starting CrCL values and were thus considered as two separate regimens for the analysis
N: no; Y: yes
A graphical representation of the dose percentages (dose administered divided by recommended
single-agent renal dose) for the renal drugs in the combinations for the initial dose is shown in
Figures 2A, 2C and for the final dose in Figures 2B, 2D. For the initial dose, the median dose
percentage was 100% for the cytotoxic - tolerated (n = 12 drugs), cytotoxic - not tolerated (n =
12 drugs), and the targeted - tolerated (n = 6 drugs) groups, and 95% for the targeted - not
tolerated (n = 8 drugs) groups with no difference seen between the groups. For the final dose,
the median dose percentage was 100% for each group (cytotoxic - tolerated (n = 13 drugs),
cytotoxic - not tolerated (n = 11 drugs), targeted - tolerated (n = 7 drugs), and targeted - not
tolerated (n = 7 drugs)) and no significant differences were seen between the groups. There
were also no significant differences in dose percentage given observed between regimens that
were tolerated (initial dose: n = 18, final dose: n = 20 drugs) versus not tolerated (initial dose: n
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= 20 drugs, final dose: n = 18 drugs) and targeted (n = 14 drugs) versus cytotoxic (n = 24 drugs)
regimens (initial dose: p = 0.49, final dose: p = 0.80). Tolerability was not found to be affected by
dosing higher than recommended or lower than recommended (Table 4). Thus, tolerability was
not found to be related to or affected by the dose of the renal agent, although this may be
secondary to the small sample size of the pilot study.
FIGURE 2: Dose Percentages of Drugs Requiring Dose
Reductions for Renal Failure
The type of regimen was compared to A) initial (p = 0.57) and B) final dose percentages (p = 0.38),
while tolerability was compared to C) initial (p = 0.89) and D) final dose percentages (p = 0.97) with
no significant differences seen between the groups. Regimens containing more than one renally
cleared drug are represented as separate points on the graph.
Dose percentage: (dose administered divided by standard dose recommended for the current renal
function) x 100. Regimens that were not tolerated either had multiple delays in administration, were
discontinued due to toxicity, or were explicitly stated by the physician to be poorly tolerated. Dose
percentages above 200 were assigned a value of 200 (n = 1) for the graph. No significant
differences were seen between the groups.
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 Tolerateda Not tolerateda Tolerated p-value
Initial dosing versus tolerability and outcome
Lower than/equal to the recommended dose (N = 26 drugs) b, c 14 12
0.31
Higher than the recommended dose (N = 12 drugs) 4 8
Lower than the recommended dose (N = 10 drugs) 4 6
0.72
Higher than/equal to the recommended dose (N = 28 drugs) 14 14
Final dosing versus tolerability and outcome
Lower than/equal to the recommended dose (N = 29 drugs) 17 12
0.7
Higher than the recommended dose (N = 9 drugs) 4 5
Lower than the recommended dose (N = 12 drugs) 6 6
0.73
Higher than/equal to the recommended dose (N = 26 drugs) 11 15
TABLE 4: Dosing Versus Tolerability and Outcome
a Regimens that were not tolerated had multiple delays in administration, were discontinued due to toxicity, or were explicitly stated by
the physician to be poorly tolerated were listed as not tolerated; b Dose percentage (dose administered divided by standard dose
recommended for the current renal function) x 100 of 100% were at the recommended renal dose, those greater than 100% were
higher than the recommended renal dose, and those less than 100% were less than the recommended renal dose; c Three subjects
had more than one drug requiring dose reduction for renal dysfunction in the combination
N: number
Discussion
Combination therapy in oncology is essential to improve outcomes and limit resistance.
However, dosing of combination therapy can be challenging. The current trend of dosing
combination therapy is a restrictive approach, which focuses on strategic dosing and drug
administration in order to spare normal cells, while simultaneously creating a targeted
cytotoxic effect on cancer cells [11]. Recent studies have demonstrated that the tolerability of
drugs may change when given in combination, necessitating dose reductions for novel
combinations [12-15]. However, these studies did not address organ dysfunction nor inform
about appropriate dosing reductions for combination therapy. Many oncology therapeutics
undergo renal clearance and moderate to severe renal dysfunction often occurs in patients with
cancer. Thus, understanding how to administer anti-cancer therapies in the setting of organ
dysfunction is important to provide safe and efficacious therapies.
The current pilot study aimed to determine dosing and tolerability for oncology patients with
renal dysfunction receiving combination therapy in a university-based practice environment. It
focused on renally cleared agents given in combination therapy to patients with moderate and
severe renal dysfunction and determined how dose reductions compared to standard single-
agent renal dose reduction recommendations, as well as how well the combinations were
tolerated. The renal agent was given at the recommended single-agent dose reduction for renal
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failure in only slightly less than half of the combinations. No significant differences were found
in the initial or final dose percentages administered between exclusively cytotoxic regimens
versus those including targeted agents or with tolerability of the regimen. The majority of the
exclusively cytotoxic regimens were administered at the single-agent recommended renal dose,
and these regimens were better tolerated than regimens with targeted agents. This is likely due
to the fact that fewer drugs were in the cytotoxic regimens (median: two vs. three drugs) and
many of these regimens contained carboplatin, which is dosed based on renal
function. Interestingly, despite the fact that many of the regimens were poorly tolerated
(defined by delays in administration, discontinuation due to toxicity, or comments in physician
notes), dose reductions of the renal agent were not routinely made to improve tolerability in
the majority of cases. The regimens were discontinued or drugs were removed rather than
attempting a dose reduction. Dose reduction of the non-renal agent was also uncommon among
regimens that were not tolerated.
Carboplatin was the most commonly used renally cleared drug, and the dose was personalized
for renal function (n = 24 combinations). Three regimens started at more than 100% of the dose
and all were dose-reduced for toxicity, while one regimen started at 80% of the renal dose with
a subsequent increase to the full renal dose. Lower doses were given due to other co-
morbidities in some cases. The final doses ranged from 50% - 100% of the renal recommended
dose with nine of the 24 regimens dosing carboplatin at less than 100% of the single-agent
renal recommended dose.  
Renal dysfunction justifying dose modification occurs frequently in patients with cancer. The
majority of renal dose reductions occur in moderate to severe renal dysfunction (glomerular
filtration rate (GFR) < 60 mL/min/1.73 m2) [10]. The first and second Renal Insufficiency and
Cancer Medications studies (IRMA-1 and IRMA-2) were cohort studies of close to 5,000 patients
each which looked at the prevalence of renal insufficiency in oncology patients and found
16.6% and 11.9% of patients had GFR values in this range, respectively [5, 16]. Other studies
have demonstrated GFR levels < 60 mL/min/1.73 m2 of 22.0% [17], 16.1% [18], and 14.7% [19].
Given the prevalence of renal dysfunction in the oncology patient population, it was surprising
that so few combinations were found in the UCSD PREDICT database. This may reflect the
avoidance of drugs with a renal clearance in this population.
The IRMA-2 study also demonstrated a reduced survival for cancer patients with renal
dysfunction (16.4 vs. 25.0 months) and higher rates of dose-related adverse events [20]. Chen et
al. found that 35% of colorectal cancer patients with normal creatinine values had a GFR less
than 60 mL/hr [21], which led to a longer toxicity duration and the development of significantly
more Grade 1 and 2 toxicities. In contrast, a study by Lichtman et al. of elderly patients with
early breast cancer receiving either cyclophosphamide/doxorubicin (AC) or
cyclophosphamide/methotrexate/fluorouracil (CMF) found no significant effect on relapse-free
or overall survival with lower calculated GFRs [22].
The current pilot study is limited by a small sample size. Thus. the results may not be
generalizable and were too small to accurately assess outcome differences with dosing. The
majority of regimens had carboplatin as the renally cleared drug, but the dose adjustments of
other drugs may be different. Due to the retrospective nature of the study, it was difficult to
determine why the renal dose reductions differed from single-agent recommendations, and the
use of these drugs in renal dysfunction may be limited as physicians opted to use alternative
therapies and regimens. 
Conclusions
In conclusion, the current pilot study demonstrated significant variability in dose adjustments
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for renally cleared drugs given in combination therapy in the presence of renal dysfunction,
even for carboplatin. Toxicity was seen particularly in combinations with targeted agents. The
regimen or a drug in the combination was discontinued to address toxicity rather than
attempting a dose reduction in the majority of cases. Additional studies are needed to
determine the appropriate dosing adjustments for renally cleared agents given in combination
therapy to patients with renal dysfunction.
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